GTCM
AVTX icon

Gyon Technologies Capital Management’s Avalo Therapeutics AVTX Stock Holding History

Gyon Technologies Capital Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6
Closed -$13K – 467
2022
Q1 		$13K Buy
+6
New +$15.1K 0.01% 262

Other funds holding AVTX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gyon Technologies Capital Management's AVTX Position: Q2 2022 in Review

Gyon Technologies Capital Management sold out of Avalo Therapeutics (AVTX) in Q2 2022, closing a stake of 6 shares — an estimated $13K sold.

Gyon Technologies Capital Management first reported a position in AVTX in Q1 2022 and held it in 1 quarter. The position peaked at $13K in Q1 2022. 43 funds tracked by Wall St. Rank hold AVTX as of Q2 2022.

  • Gyon Technologies Capital Management reported no remaining Avalo Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 6 Avalo Therapeutics shares in Q2 2022, an estimated $13K.
  • Gyon Technologies Capital Management first reported a position in Avalo Therapeutics in Q1 2022 and held it in 1 quarter.
  • Gyon Technologies Capital Management's Avalo Therapeutics position peaked at $13K in Q1 2022.
  • 43 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2022.

Based on Gyon Technologies Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.